Evidence map›Paper›PMID 33930107›Full record

ArticleEuropean heart journal. Cardiovascular pharmacotherapy2021

Aspirin-free antiplatelet regimens after PCI: insights from the GLOBAL LEADERS trial and beyond.

Rutao Wang, Sijing Wu, Amr Gamal, Chao Gao, Hironori Hara, Hideyuki Kawashima, Masafumi Ono, Robert-Jan van Geuns, Pascal Vranckx, Stephan Windecker and 3 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European heart journal. Cardiovascular pharmacotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. P2YNature reviews. Cardiology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 8 countries.

Rutao WangDepartment of Cardiology, Xijing Hospital, Changle West Road 127, Xi'an 710032, China.
Sijing WuDepartment of Cardiology, National University of Ireland, Galway (NUIG), University Road, Galway H91 TK33, Ireland.
Amr GamalDepartment of Cardiology, National University of Ireland, Galway (NUIG), University Road, Galway H91 TK33, Ireland.
Chao GaoDepartment of Cardiology, Xijing Hospital, Changle West Road 127, Xi'an 710032, China.
Hironori HaraDepartment of Cardiology, National University of Ireland, Galway (NUIG), University Road, Galway H91 TK33, Ireland.
Hideyuki KawashimaDepartment of Cardiology, National University of Ireland, Galway (NUIG), University Road, Galway H91 TK33, Ireland.
Masafumi OnoDepartment of Cardiology, National University of Ireland, Galway (NUIG), University Road, Galway H91 TK33, Ireland.
Robert-Jan van GeunsDepartment of Cardiology, Radboud University Medical Center, Geert Grooteplein Zuid 8, 6525 GA Nijmegen, The Netherlands.
Pascal VranckxDepartment of Cardiology and Critical Care Medicine, Hartcentrum Hasselt, Jessa Ziekenhuis, Stadsomvaart 11, 3500 Hasselt, Belgium.
Stephan WindeckerDepartment of Cardiology, Bern University Hospital, Freiburgstrasse 4, 3010 Bern, Switzerland.ORCID 0000-0003-2653-6762
Yoshinobu OnumaDepartment of Cardiology, National University of Ireland, Galway (NUIG), University Road, Galway H91 TK33, Ireland.
Patrick W SerruysDepartment of Cardiology, National University of Ireland, Galway (NUIG), University Road, Galway H91 TK33, Ireland.ORCID 0000-0002-9636-1104
Scot GargDepartment of Cardiology, East Lancashire Hospitals NHS Trust, Haslingden Rd, Blackburn BB2 3HH, Lancashire, UK.
Ollscoil na Gaillimhe – University of Galway · IERadboud University Nijmegen · NLEast Lancashire Hospitals NHS Trust · GBJessa Hospital · BEUniversity Hospital of Bern · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Historically, aspirin has been the primary treatment for the prevention of ischaemic events in patients with coronary artery disease. For patients undergoing percutaneous coronary intervention (PCI) standard treatment has been 12 months of dual antiplatelet therapy (DAPT) with aspirin and clopidogrel, followed by aspirin monotherapy; however, DAPT is undeniably associated with an increased risk of bleeding. For over a decade novel P2Y12 inhibitors, which have increased specificity, potency, and efficacy have been available, prompting studies which have tested whether these newer agents can be used in aspirin-free antiplatelet regimens to augment clinical benefits in patients post-PCI. Among these studies, the GLOBAL LEADERS trial is the largest by cohort size, and so far has provided a wealth of evidence in a variety of clinical settings and patient groups. This article summarizes the state-of-the-art evidence obtained from the GLOBAL LEADERS and other trials of aspirin-free strategies.

Indexed as

Percutaneous Coronary InterventionPlatelet Aggregation InhibitorsAspirinClinical Trials as TopicClopidogrelDual Anti-Platelet TherapyHumansAspirinClopidogrelPlatelet Aggregation InhibitorsAspirin-free therapyGLOBAL LEADERSP2Y12 inhibitorPercutaneous coronary interventionRandomized clinical trials

Identifiers

PMID33930107
PMCPMC8566303
OpenAlexW3159547257

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.